A Next-Gen Polymer Therapeutic

Our proprietary POZ platform is based on a synthetic, water soluble, low viscosity polymer called poly (2-oxazoline). During the synthesis steps, a predictable amount of drug is incorporated on the backbone of the polymer using pendant alkyne groups and metal catalyzed “click chemistry”.

POZ technology provides greater control in drug loading, and the rate of release of attached drugs can often be more precisely controlled. Drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood. The technology is optimized for small molecules and can also be applied to proteins, aptamers and other classes of molecules.

POZ Delivers Key Advantages

POZ is engineered to address the limitations of PEG (polyethylene glycol) and other biocompatible polymers – such as immunogenicity, where unlike PEG, POZ does not elicit an immune response or stimulate development of antibodies to the polymer itself.

Immunogenicity

Does not elicit an immune response or stimulate development of antibodies

Drug Loading

Enables considerably greater drug loading with almost all drugs – current focus on phenolic hydroxyls

Release

Programmable drug release kinetics enable continuous delivery

Accumulation

Does not accumulate in tissues, is not metabolized, clears through renal filtration

Synthesis and Stability

Uses safe, inexpensive materials in a “one pot” synthesis and is stable at room temperature

Enabling Continuous Drug Delivery and Why It Matters

Many drugs, for example those used to treat neurological disorders like Parkinson’s, have narrow therapeutic ranges in which they can work safely and efficaciously. They are often dosed more frequently – resulting in large and frequent fluctuations in drug exposure. They have to be monitored and dose adjusted with greater frequency, and on an individual basis. These fluctuations present clinical, compliance and quality of life challenges for many patients.

Administered Subcutaneously, POZ Provides Extended Delivery

Join Us.

We’re pioneering bold new science.

Partners Investors Contact